Physician profile
Aaron Young
NPI 1750504734
$6,122.99
in general payments reported to CMS, 2019-2025
48 companies · $781 in 2025
The $781 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,577 · 2020: $359 · 2021: $441 · 2022: $872 · 2023: $855 · 2024: $1,238 · 2025: $781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,848 · Education: $25.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,847.60 |
| Education | $25.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $861.66 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $830.35 | 2020-2025 | Vraylar, Ubrelvy, Linzess |
| Lilly USA, LLC | $633.49 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $367.72 | 2019-2025 | Airsupra, Farxiga |
| Merck Sharp & Dohme LLC | $342.83 | 2019-2025 | Vaxneuvance, Gardasil 9, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $291.78 | 2019-2025 | Jardiance |
| Sunovion Pharmaceuticals INC. | $268.51 | 2019-2022 | |
| Pfizer INC. | $248.04 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $240.74 | 2019-2023 | |
| Amgen INC. | $217.68 | 2019-2024 | Otezla, Repatha |
| Mylan Specialty L.P. | $195.55 | 2019-2024 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $163.12 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $118.12 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $112.58 | 2023-2024 | Gemtesa |
| Astellas Pharma US INC | $104.50 | 2019-2024 | Veozah, Myrbetriq |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.